Wikidata:Database reports/Constraint violations/P3355
Jump to navigation
Jump to search
Constraint violations report for negative therapeutic predictor for (Discussion, uses, items, changes, related properties): the presence of the genetic variant helps to predict no response or resistance to a treatment
Data time stamp: (UTC) — Items processed: 467
The report is generated based on the settings on Property:P3355#P2302.
Updates overwrite this page. Some may already be fixed since the last update: check RecentChangesLinked.
When incremental dumps and the bot work as planned, items fixed before 07:00 UTC disappear in the next update. The report is not updated if only the item count changes.
The report can include false positives. There is no need to "fix" them.
Data time stamp: (UTC) — Items processed: 467
The report is generated based on the settings on Property:P3355#P2302.
Updates overwrite this page. Some may already be fixed since the last update: check RecentChangesLinked.
When incremental dumps and the bot work as planned, items fixed before 07:00 UTC disappear in the next update. The report is not updated if only the item count changes.
The report can include false positives. There is no need to "fix" them.
"Scope" violations[edit]
Violations count: 0
"Type sequence variant (Q15304597)" violations[edit]
Violations count: 52
- ERBB2 Amplification (Q27908387): Transcript Amplification (Q27907091)
- TP53 DNA Binding Domain Mutation (Q28371205): DNA binding site (Q5205743)
- EGFR VIII (Q28371264): disruptive inframe deletion (Q42866969)
- FLT3 TKD MUTATION (Q28381821): Nonsynonymous Variant (Q27905684)
- NF2 Y177fs (Q28382165): Frameshift Elongation (Q28381989)
- FNTB RS11623866 (Q28382220): Regulatory Region Variant (Q28381988)
- KRAS RS61764370 (Q28420832): 3 Prime UTR Variant (Q28419124)
- TYMS 5' TANDEM REPEAT (Q28421466): 5 Prime UTR Variant (Q27919343), Short Tandem Repeat Variation (Q28419126)
- CCND1 Amplification (Q28444926): Transcript Amplification (Q27907091)
- CCNE1 Amplification (Q28444962): Transcript Amplification (Q27907091)
- EGFR Amplification (Q28444964): Transcript Amplification (Q27907091)
- PIK3CA Amplification (Q28444974): Transcript Amplification (Q27907091)
- BIRC7 AMPLIFICATION (Q28444989): Transcript Amplification (Q27907091)
- FGFR1 Amplification (Q28444992): Transcript Amplification (Q27907091)
- MET Amplification (Q28444994): Transcript Amplification (Q27907091)
- RSF1 AMPLIFICATION (Q28445054): Transcript Amplification (Q27907091)
- TYMS Amplification (Q28445070): Transcript Amplification (Q27907091)
- ABCC3 AMPLIFICATION (Q28445094): Transcript Amplification (Q27907091)
- KIT Amplification (Q28445161): Transcript Amplification (Q27907091)
- KRAS Amplification (Q28445165): Transcript Amplification (Q27907091)
- SMAD4 Deletion (Q28445190): Transcript Ablation (Q28381986)
- GNAS c.393T>C (Q29938321): Synonymous Variant (Q28419125)
- BRAF Amplification (Q29938769): Transcript Amplification (Q27907091)
- NTRK1 Amplification (Q29938785): Transcript Amplification (Q27907091)
- NTRK3 Amplification (Q29938787): Transcript Amplification (Q27907091)
- ABL1 C475V (Q32965441): Splice Donor Variant (Q29937349)
- JAK2 Splice Site (c.1641+2T>G) (Q32965598): Splice Donor Variant (Q29937349)
- BRAF intron 9 rearrangement (Q50092874):
- BRAF intron 10 rearrangement (Q50092876):
- ASS1 LOSS (Q56240990):
- AKT1 Overexpression (Q56241018):
- BRAF V600E/K and Amplification (Q56241020):
- PIK3R2 OVEREXPRESSION (Q56241021):
- ABL1 TKD MUTATION (Q56241029):
- ABL1 P-Loop Mutation (Q56241031):
- ABL1 Non-P-Loop Mutation (Q56241032):
- BRAF D594K (Q56241039):
- PDGFRA D842_H845DELDIMH (Q66084442):
- BRAF Exon 15 Mutation (Q66084580):
- KIT V555_V559DEL (Q66084585):
- KIT K550_K559DEL (Q66084586):
- EGFR Wildtype (Q79419097): wild type (Q128723)
- KRAS A146 (Q88412581):
- ABL1 Double Ph (Q92591933):
- ATM c.902-1G>T (Q96008397):
- ATM c.7089+1del (Q96008404):
- ATM c.7515+1_2del (Q96008412):
- FLT3 Y842C (Q98713568):
- FLT3 F691L (Q99542856):
- KRAS Wildtype (Q99542858): wild type (Q128723)
- EGFR D770delinsGY (Q105669006):
- LYN OVEREXPRESSION (Q105669095):
Types statistics[edit]
"Entity types" violations[edit]
Violations count: 0
"Value type chemical compound (Q11173)" violations[edit]
Violations count: 86
- BRAF V600E (Q21851559): irinotecan (Q412197): type of chemical entity (Q113145171), Irinotecan (Q26989371)
- ABL1 BCR::ABL T315I (Q27906612): dasatinib monohydrate / imatinib mesylate combination therapy (Q55754263): combination therapy (Q1304270)
- ABL1 BCR::ABL T315I (Q27906612): imatinib mesylate / nilotinib combination therapy (Q58643349): combination therapy (Q1304270)
- ABL1 BCR::ABL T315I (Q27906612): dasatinib monohydrate / imatinib mesylate combination therapy (Q55754263): combination therapy (Q1304270)
- ABL1 BCR::ABL T315I (Q27906612): Dasatinib / Nilotinib combination therapy (Q42159395): combination therapy (Q1304270)
- ABL1 BCR::ABL E255K (Q27906817): dasatinib monohydrate / imatinib mesylate combination therapy (Q55754263): combination therapy (Q1304270)
- NRAS Q61L (Q27908351): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- KRAS Exon 2 Mutation (Q27908371): erlotinib / gemcitabine combination therapy (Q44738697): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Cetuximab / capecitabine / Oxaliplatin combination therapy (Q58645227): combination therapy (Q1304270)
- ESR1 L536Q (Q28370986): hormone therapy (Q1628266): medical treatment (Q179661), opotherapy (Q56315482), gender-affirming care (Q123822804)
- ESR1 D538G (Q28370987): hormone therapy (Q1628266): medical treatment (Q179661), opotherapy (Q56315482), gender-affirming care (Q123822804)
- ESR1 Y537C (Q28370988): hormone therapy (Q1628266): medical treatment (Q179661), opotherapy (Q56315482), gender-affirming care (Q123822804)
- ESR1 Y537N (Q28370989): hormone therapy (Q1628266): medical treatment (Q179661), opotherapy (Q56315482), gender-affirming care (Q123822804)
- ESR1 Y537S (Q28370991): hormone therapy (Q1628266): medical treatment (Q179661), opotherapy (Q56315482), gender-affirming care (Q123822804)
- KRAS G12/G13 (Q28371010): trametinib / gemcitabine combination therapy (Q44738705): combination therapy (Q1304270)
- KRAS G12/G13 (Q28371010): irinotecan (Q412197): type of chemical entity (Q113145171), Irinotecan (Q26989371)
- KRAS G12/G13 (Q28371010): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- KRAS G12C (Q28371011): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- NRAS Q61 (Q28371022): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- PIK3CA E545K (Q28371031): Trastuzumab / Lapatinib combination therapy (Q38160367): combination therapy (Q1304270)
- PIK3CA Exon 21 Mutation (Q28371032): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- PIK3CA Exon 10 Mutation (Q28371033): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- PIK3CA H1047R (Q28371034): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- PIK3CA H1047R (Q28371034): Trastuzumab / Lapatinib combination therapy (Q38160367): combination therapy (Q1304270)
- WT1 EXON 7 MUTATION (Q28371049): cytarabine / daunorubicin combination therapy (Q44843674): combination therapy (Q1304270)
- EGFR VIII (Q28371264): docetaxel trihydrate / Cetuximab combination therapy (Q44843818): combination therapy (Q1304270)
- DKK1 NUCLEAR EXPRESSION (Q28371292): fluorouracil / irinotecan / Oxaliplatin / levoleucovorin combination therapy (Q44843849): combination therapy (Q1304270)
- NRAS Q61K (Q28371390): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- PML PML::RARA A216V (Q28371426): ortho-arsenite ion (Q26841209): type of chemical entity (Q113145171), oxyanion (Q3269344)
- KRAS G12R (Q28371486): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- BRAF D594G (Q28371565): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- BRAF D594G (Q28371565): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- ESR1 S463P (Q28371611): aromatase inhibitor (Q3040305): class of chemical entities with similar applications or functions (Q56256173), estrogen antagonist (Q50429983), steroid synthesis inhibitor (Q50430472), oxidoreductase inhibitor (Q66587127)
- TYMS 5' TANDEM REPEAT (Q28421466): fluorouracil / irinotecan combination therapy (Q44843772): combination therapy (Q1304270)
- VHL MUTATION (Q28444948): anti vascular endothelial growth factor therapy (Q23808471): medical treatment (Q179661)
- NRAS Mutation (Q28444972): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- PTEN Loss (Q28444976): chemotherapy (Q974135): treatment of cancer (Q2575340), chemiotherapy (Q3252988)
- CD274 Expression (Q28444998): Adaptive radiation therapy (Q180507): medical specialty (Q930752), medical treatment (Q179661), treatment of cancer (Q2575340)
- PIK3CA Mutation (Q28445019): irinotecan (Q412197): type of chemical entity (Q113145171), Irinotecan (Q26989371)
- PIK3CA Mutation (Q28445019): capecitabine / lapatinib combination therapy (Q58645278): combination therapy (Q1304270)
- PIK3CA Mutation (Q28445019): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- PIK3CA Mutation (Q28445019): cyclophosphamide hydrate / doxorubicin / fluorouracil / epirubicin / paclitaxel combination therapy (Q58645374): combination therapy (Q1304270)
- PTEN Expression (Q28445020): Fulvestrant / everolimus combination therapy (Q44843816): combination therapy (Q1304270)
- AREG Expression (Q28445022): docetaxel trihydrate / Cetuximab combination therapy (Q44843818): combination therapy (Q1304270)
- KRAS Mutation (Q28445037): chemotherapy / Bevacizumab combination therapy (Q44843843): combination therapy (Q1304270)
- KRAS Mutation (Q28445037): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- MDM2 EXPRESSION (Q28445042): cisplatin / pemetrexed combination therapy (Q44843854): combination therapy (Q1304270)
- BRAF Mutation (Q28445087): irinotecan (Q412197): type of chemical entity (Q113145171), Irinotecan (Q26989371)
- BRAF Mutation (Q28445087): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- VHL LOSS (Q28445107): anti vascular endothelial growth factor therapy (Q23808471): medical treatment (Q179661)
- STK11 LOSS (Q28445123): selumetinib / docetaxel trihydrate combination therapy (Q44738713): combination therapy (Q1304270)
- KRAS Q61 (Q28531489): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- ARAF S490T (Q29938046): Irinotecan / Vemurafenib / Cetuximab combination therapy (Q43387526): combination therapy (Q1304270)
- GNAS R201C (Q29938047): Irinotecan / Vemurafenib / Cetuximab combination therapy (Q43387526): combination therapy (Q1304270)
- GNAS c.393T>C (Q29938321): fluorouracil / cisplatin combination therapy (Q44843692): combination therapy (Q1304270)
- NRAS G12D (Q29938324): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- PIK3CA E545Q (Q29938330): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- PIK3CA Q546K (Q29938337): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- NRAS Q61H (Q29938347): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- NRAS G13R (Q29938349): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- NRAS G12C (Q29938351): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- KRAS A146P (Q29938360): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- KRAS Q61H (Q29938363): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- KRAS Q61L (Q29938364): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- KRAS Q61R (Q29938366): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- KRAS Q61K (Q29938368): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- ABL1 BCR::ABL L248V (Q29938511): imatinib mesylate / nilotinib combination therapy (Q58643349): combination therapy (Q1304270)
- ABL1 BCR::ABL Y253H (Q29938515): imatinib mesylate / nilotinib combination therapy (Q58643349): combination therapy (Q1304270)
- PIK3CA H1047L (Q29938665): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- ABL1 BCR::ABL F359C (Q29938707): imatinib mesylate / nilotinib combination therapy (Q58643349): combination therapy (Q1304270)
- ABL1 BCR::ABL V299L (Q29938716): dasatinib monohydrate / imatinib mesylate combination therapy (Q55754263): combination therapy (Q1304270)
- BRAF Amplification (Q29938769): dabrafenib / Panitumumab combination therapy (Q44844326): combination therapy (Q1304270)
- BRAF Amplification (Q29938769): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- PIK3CA R93W (Q32949004): cetuximab / oxaliplatin / fluorouracil combination therapy (Q104539092): combination therapy (Q1304270)
- PIK3CA S158L (Q32964927): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
- PIK3CA E81K (Q32964931): cetuximab / oxaliplatin / fluorouracil combination therapy (Q104539092): combination therapy (Q1304270)
- ABL1 BCR::ABL F311L (Q32965028): imatinib mesylate / nilotinib combination therapy (Q58643349): combination therapy (Q1304270)
- ABL1 BCR::ABL H396P (Q32965040): imatinib mesylate / nilotinib combination therapy (Q58643349): combination therapy (Q1304270)
- chr9:g.133748282A>G (ABL1:p.T315A) (Q38105235): dasatinib (Q419940): type of chemical entity (Q113145171), tyrosine-kinase inhibitor (Q906415)
- chr9:g.133748288T>G (ABL1:p.F317V) (Q38152931): dasatinib (Q419940): type of chemical entity (Q113145171), tyrosine-kinase inhibitor (Q906415)
- chr9:g.133748288T>A (ABL1:p.F317I) (Q38152933): dasatinib (Q419940): type of chemical entity (Q113145171), tyrosine-kinase inhibitor (Q906415)
- chr9:g.133748289T>G (ABL1:p.F317C) (Q38152934): dasatinib (Q419940): type of chemical entity (Q113145171), tyrosine-kinase inhibitor (Q906415)
- ASS1 LOSS (Q56240990): platinum as an investment (Q691671): price (Q160151)
- BRAF D594K (Q56241039): irinotecan (Q412197): type of chemical entity (Q113145171), Irinotecan (Q26989371)
- KRAS A146 (Q88412581): cetuximab / chemotherapy combination therapy (Q88403694): combination therapy (Q1304270)
- PIK3CA R88Q (Q104539001): irinotecan / Cetuximab combination therapy (Q68215488): combination therapy (Q1304270)
Types statistics[edit]
"Mandatory Qualifiers" violations[edit]
Violations count: 0
"Mandatory Qualifiers" violations[edit]
Violations count: 77
- ABL1 V289I (Q32965306): rating (P4271)
- ABL1 Y342H (Q32965310): rating (P4271)
- ABL1 Y393C (Q32965330): rating (P4271)
- chr9:g.133748282A>G (ABL1:p.T315A) (Q38105235): rating (P4271)
- chr9:g.133748288T>G (ABL1:p.F317V) (Q38152931): rating (P4271)
- chr9:g.133748288T>G (ABL1:p.F317V) (Q38152931): rating (P4271)
- chr9:g.133748288T>A (ABL1:p.F317I) (Q38152933): rating (P4271)
- chr9:g.133748288T>A (ABL1:p.F317I) (Q38152933): rating (P4271)
- chr9:g.133748289T>G (ABL1:p.F317C) (Q38152934): rating (P4271)
- chr9:g.133748289T>G (ABL1:p.F317C) (Q38152934): rating (P4271)
- chr9:g.133738325T>C (ABL1:p.I242T) (Q38153057): rating (P4271)
- chr9:g.133738340A>G (ABL1:p.K247R) (Q38153111): rating (P4271)
- chr9:g.133738348G>A (ABL1:p.G250R) (Q38153113): rating (P4271)
- chr9:g.133738355A>G (ABL1:p.Q252R) (Q38153114): rating (P4271)
- chr9:g.133738356G>T (ABL1:p.Q252H) (Q38153115): rating (P4271)
- chr9:g.133738309A>G (ABL1:p.M237V) (Q38153116): rating (P4271)
- chr9:g.133738374G>C (ABL1:p.E258D) (Q38153118): rating (P4271)
- chr9:g.133738382G>T (ABL1:p.W261L) (Q38153119): rating (P4271)
- chr9:g.133738417T>A (ABL1:p.L273M) (Q38153120): rating (P4271)
- chr9:g.133747516G>A (ABL1:p.E275K) (Q38153122): rating (P4271)
- chr9:g.133747516G>C (ABL1:p.E275Q) (Q38153124): rating (P4271)
- chr9:g.133747522A>G (ABL1:p.T277A) (Q38153126): rating (P4271)
- chr9:g.133747528G>A (ABL1:p.E279K) (Q38153128): rating (P4271)
- chr9:g.133747532T>C (ABL1:p.V280A) (Q38153129): rating (P4271)
- chr9:g.133747559T>C (ABL1:p.V289A) (Q38153131): rating (P4271)
- chr9:g.133747567G>C (ABL1:p.E292Q) (Q38153132): rating (P4271)
- chr9:g.133747570A>G (ABL1:p.I293V) (Q38153133): rating (P4271)
- chr9:g.133747585C>G (ABL1:p.L298V) (Q38153134): rating (P4271)
- chr9:g.133748270T>C (ABL1:p.F311L) (Q38153136): rating (P4271)
- chr9:g.133748270T>A (ABL1:p.F311I) (Q38153137): rating (P4271)
- chr9:g.133748298A>G (ABL1:p.Y320C) (Q38153139): rating (P4271)
- chr9:g.133748310T>A (ABL1:p.L324Q) (Q38153140): rating (P4271)
- chr9:g.133748367T>C (ABL1:p.M343T) (Q38153141): rating (P4271)
- chr9:g.133748370C>T (ABL1:p.A344V) (Q38153142): rating (P4271)
- chr9:g.133748388C>T (ABL1:p.A350V) (Q38153143): rating (P4271)
- chr9:g.133748404G>C (ABL1:p.E355D) (Q38153144): rating (P4271)
- chr9:g.133748403A>G (ABL1:p.E355G) (Q38153146): rating (P4271)
- chr9:g.133748403A>C (ABL1:p.E355A) (Q38153147): rating (P4271)
- chr9:g.133748414T>A (ABL1:p.F359I) (Q38153149): rating (P4271)
- chr9:g.133748414T>A (ABL1:p.F359I) (Q38153149): rating (P4271)
- chr9:g.133748414T>C (ABL1:p.F359L) (Q38153150): rating (P4271)
- chr9:g.133750256G>T (ABL1:p.D363Y) (Q38153152): rating (P4271)
- chr9:g.133750259C>A (ABL1:p.L364I) (Q38153153): rating (P4271)
- chr9:g.133750263C>T (ABL1:p.A365V) (Q38153154): rating (P4271)
- chr9:g.133750266C>G (ABL1:p.A366G) (Q38153156): rating (P4271)
- chr9:g.133750278T>C (ABL1:p.L370P) (Q38153158): rating (P4271)
- chr9:g.133750281T>C (ABL1:p.V371A) (Q38153159): rating (P4271)
- chr9:g.133750286G>A (ABL1:p.E373K) (Q38153160): rating (P4271)
- chr9:g.133750307G>A (ABL1:p.A380T) (Q38153162): rating (P4271)
- chr9:g.133750313T>C (ABL1:p.F382L) (Q38153163): rating (P4271)
- chr9:g.133750328T>A (ABL1:p.L387M) (Q38153164): rating (P4271)
- chr9:g.133750330G>T (ABL1:p.L387F) (Q38153165): rating (P4271)
- chr9:g.133750328T>G (ABL1:p.L387V) (Q38153166): rating (P4271)
- chr9:g.133750331A>C (ABL1:p.M388L) (Q38153168): rating (P4271)
- chr9:g.133750356A>C (ABL1:p.H396P) (Q38153169): rating (P4271)
- chr9:g.133750358G>C (ABL1:p.A397P) (Q38153274): rating (P4271)
- chr9:g.133750419C>T (ABL1:p.S417F) (Q38153275): rating (P4271)
- chr9:g.133750419C>A (ABL1:p.S417Y) (Q38153276): rating (P4271)
- chr9:g.133750422T>G (ABL1:p.I418S) (Q38153277): rating (P4271)
- chr9:g.133750421A>G (ABL1:p.I418V) (Q38153279): rating (P4271)
- chr9:g.133753828G>A (ABL1:p.A433T) (Q38153280): rating (P4271)
- chr9:g.133753844C>G (ABL1:p.S438C) (Q38153282): rating (P4271)
- chr9:g.133753879G>A (ABL1:p.E450K) (Q38153284): rating (P4271)
- chr9:g.133753880A>G (ABL1:p.E450G) (Q38153285): rating (P4271)
- chr9:g.133753880A>C (ABL1:p.E450A) (Q38153286): rating (P4271)
- chr9:g.133753880A>T (ABL1:p.E450V) (Q38153288): rating (P4271)
- chr9:g.133753888G>A (ABL1:p.E453K) (Q38153289): rating (P4271)
- chr9:g.133753889A>G (ABL1:p.E453G) (Q38153290): rating (P4271)
- chr9:g.133753889A>C (ABL1:p.E453A) (Q38153292): rating (P4271)
- chr9:g.133753889A>T (ABL1:p.E453V) (Q38153293): rating (P4271)
- chr9:g.133753906G>A (ABL1:p.E459K) (Q38153295): rating (P4271)
- chr9:g.133753907A>G (ABL1:p.E459G) (Q38153296): rating (P4271)
- chr9:g.133753907A>C (ABL1:p.E459A) (Q38153297): rating (P4271)
- chr9:g.133753907A>T (ABL1:p.E459V) (Q38153299): rating (P4271)
- chr9:g.133753947G>C (ABL1:p.M472I) (Q38153300): rating (P4271)
- chr9:g.133755470C>T (ABL1:p.P480L) (Q38153301): rating (P4271)
- chr9:g.133755893A>G (ABL1:p.E507G) (Q38153303): rating (P4271)
"Mandatory Qualifiers" violations[edit]
Violations count: 0